Erectile Dysfunction in Type II Diabetes: Role of Adiponectin
Project Number5R21DK073758-02
Contact PI/Project LeaderCHITALEY, KANCHAN A
Awardee OrganizationUNIVERSITY OF WASHINGTON
Description
Abstract Text
DESCRIPTION (provided by applicant): Erectile dysfunction (ED) in the type II diabetic patients is estimated to be 3 times more prevalent than in non-diabetic subjects. Basic science studies outlining mechanisms involved in ED associated with type II diabetes are very limited. In light of the increasing prevalence of type II diabetes and its complications, and the insufficient efficacy (<50%) of pharmacologic therapeutics (mainly phosphodiesterase V inhibitors) in this population, the need for further research in this field is readily apparent. Although hyperglycemia is a common feature of diabetes, additional factors related to obesity and lipid abnormalities associated with type II diabetes potentially contribute to mechanisms of ED in this cohort. Adiponectin, an adipose-produced cytokine, is important for insulin sensitization, and is decreased in obesity and in type II diabetic patients. Recent studies demonstrate that adiponectin has a vasoprotective role, increasing the bioavailability of the potent vasodilator, nitric oxide (NO). The general hypothesis of this study is that decreased adiponectin in type II diabetes contributes to altered cavernosal vasoreactivity and ED, and will be tested with the following Specific Aims: 1) To characterize erectile function in a mouse model of type II diabetes (db/db) by testing the following hypotheses: a. Db/db mice have lower intracavernosal pressure in response to electrical stimulation of the cavernous nerve in vivo as compared to controls. b. Isolated cavernosal tissue from db/db mice, compared to control, exhibits attenuated endothelium-dependent relaxation and heightened agonist-induced contraction in vitro. c. Cavernosal tissue from db/db mice exhibits increased eNOS-mediated superoxide generation and decreased NO. 2) To determine if restoration of adiponectin enhances NO bioavailability and erectile function in type II diabetic (db/db) mice by testing the following hypotheses: a. Adenoviral-mediated delivery of adiponectin, as compared to empty vector, improves erectile function in vivo. b. Isolated cavernosal tissue from db/db mice transfected with adiponectin adenovirus exhibits enhanced endothelium-dependent dilation and NO bioavailability in vitro. The knowledge gained from the proposed experiments may add to the understanding of mechanisms underlying ED in type II diabetes, and contribute to the development of more efficacious therapies to prevent ED or restore erectile function in this rapidly growing population.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
849
DUNS Number
605799469
UEI
HD1WMN6945W6
Project Start Date
01-April-2006
Project End Date
28-February-2009
Budget Start Date
01-March-2007
Budget End Date
28-February-2009
Project Funding Information for 2007
Total Funding
$226,971
Direct Costs
$145,650
Indirect Costs
$81,321
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Diabetes and Digestive and Kidney Diseases
$226,971
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21DK073758-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21DK073758-02
Patents
No Patents information available for 5R21DK073758-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21DK073758-02
Clinical Studies
No Clinical Studies information available for 5R21DK073758-02
News and More
Related News Releases
No news release information available for 5R21DK073758-02
History
No Historical information available for 5R21DK073758-02
Similar Projects
No Similar Projects information available for 5R21DK073758-02